survey high-volum pulmonologist regard use approv
doublet orkambi lumacaftor/ivacaftor homozyg heterozyg
function cystic fibrosi cf patient also gaug
satisfact risk/benefit profil orkambi potenti soon-to-
survey valid state strategi grow total cf patient current
receiv corrector/potenti like orkambi ad anoth doublet
bolu patient alreadi await tez/iva heterozyg
function cf patient could put tez/iva quickli updat
sales/earn number rais pt base heighten
certainti strong tez/iva launch stay bullish
indic earn call initi target patient
set tez/iva homozyg patient discontinu orkambi
due advers event never initi orkambi due drug risk/benefit
valid posit indic potenti bolu patient upon approv
survey indic physician
potenti wareh treatment-na homozyg patient tez/
iva approv coupl orkambi-discontinu patient heterozyg
function mutat patient await treatment
believ could bolu effect sale number
minor pulmonologist satisfi orkambi
expect much initi switch orkambi tez/iva patient
control orkambi toler treatment well well-control
patient efficacy/safeti expect quit high question profil
phase triplet data would match
among subset heterozyg function mutat patient
even kalydeco ivacaftor monotherapi avail pulmonologist express
clear need doublet tez/iva fact one-third survey
physician indic aggress uptak tez/iva indic
among best-perform stock
triplet pivot phase trial may read survey
indic meaning probabl sales/earn
number low due soft orkambi launch tez/iva
meaning chang stay bullish
global biotechnolog
compani aim discov develop
commerci innov medicin
peopl seriou diseas lead
analyst certif import disclosur see disclosur appendix
orkambi achiev patient penetr homozyg
tez/iva success approv get
homozyg penetr
slower expect eu launch orkambi franc price
late
triplet mid-stag clinic trial news flow
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex reach steadi state
could begin upsid stori
orkambi reimburs approv variou eu row
tez/iva doublet approv homozyg us
on-going updat phase
triplet phase data
initi pivot develop two triplet regimen one
once/day arm
vertex secur broad reimburs cf franchis ex-u
rapidli expect
tez/iva sale ramp faster expect
triple-combin regimen tez/iva plu anoth corrector
approv market hetmin popul
disclos addit pipelin opportun
failur secur orkambi regulatori approv australia
reimburs europ canada australia near term
lower expect uptak orkambi/tez/iva
compet regimen other abbvie/galpago
approv earlier expect take signific market share
util composit valuat methodolog biotechnolog compani util forward price-to-earnings multipl net present valu
adjust estim earn sinc biotech sector high-growth/high-expect sector aim rank target compani base
qualiti sale and/or earn growth versu peer group peer index nbi expect earn growth
next three five year well expect higher termin multipl due
perceiv greater certainti qualiti sales/earn growth appli discount rate vs peer group averag
risk outperform rate slow orkambi sale failur secur fda approv tezacaftor/ivacaftor combo
disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur doublet triplet and/or regulatori
non-approv kalydeco label extens
survey data indic
breakdown cf patient genotyp report close mirror
signific amount orkambi-usag patient one
mutat one residu function mutat heterozyg patient
howev usag driven survey pulmonologist
report almost util
substanti number treatment-nav orkambi-discontinu cf
patient could benefit tez/iva repres potenti bolu upon
total number cf patient treat cftr modul like grow
tez/iva enter market
orkambi risk/benefit profil optim support patient
physician commun thought effect mani pulmonologist
minor pulmonologist prescrib orkambi meaning heterozyg
patient cite patient/famili request potenti efficaci
despit label highlight unmet need popul
half pulmonologist report broad penetr among orkambi-elig
homozyg patient howev appear subset
appreci risk/benefit profil orkambi continu prescrib
expect pulmonologist less enthusiast toward potenti uptak
tez/iva heterozyg patient sinc kalydeco shown efficaci
penetr popul interestingli howev subgroup
pulmonologist indic aggress potenti uptak
pulmonologist felt would zero uptak tez/iva heterozyg
patient year indic definit unmet need patient
popul even kalydeco
end report survey methodolog question
question current cystic fibrosi cf patient percent
 one mutat one residu function mutat
 one mutat one minim function mutat
survey pulmonologist treat high volum cf patient breakdown
variou cf mutat report treat patient approxim mirror
academ literatur
mutat pulmonologist cite seen two
minim function mutat variou class two mutat unknown mutat
exhibit class mutat gene encod cystic fibrosi transmembran conduct
question percent current cystic fibrosi cf patient
follow genotyp prescrib orkambi
 one mutat one residu function mutat
 one mutat one minim function mutat
orkambi label us fda indic approv treatment cystic fibrosi cf
patient age year older homozyg mutat
cftr gene patient genotyp unknown fda-clear cf mutat test
use detect presenc mutat allel
survey data appar orkambi also util
homozyg patient also patient mutat
one allel anoth mutat second allel
survey data clear respond pulmonologist
drive heterozyg usag almost
usag
exhibit cf mutat subtyp treat orkambi
one respond util orkambi mutat specifi unknown
question current cystic fibrosi cf patient elig treatment
orkambi percent are/hav
 start orkambi sinc discontinu due respiratori side effect
clear survey substanti number treatment nave
orkambi discontinu patient could benefit tez/iva
survey data respond report
orkambi-elig patient treatment nave abil extrapol
data limit believ constitut potenti bolu
popul tez/iva
exhibit breakdown patient elig orkambi
vertex indic variou earn call investor meet
differ group patient could candid tezacaftor/ivacaftor
tez/iva doublet homozyg cf patient discontinu
orkambi due advers event homozyg patient never start
orkambi due drug risk/benefit profil residu function mutat patient kalydeco
current approv patient earn call
believ grow total number cf patient treat cftr
modul tez/iva
question cf patient current prescrib orkambi percentag would
character follow treatment outcom
highli effect well toler
 effect well toler effect somewhat well toler
 moder effect well toler
moder effect somewhat well toler
 effect poorli toler
 moder effect poorli toler
 poor efficaci toler
survey respond felt orkambi effect felt
toler line commentari orkambi
risk/benefit profil optim support patient physician commun
question percent cf patient one mutat one
residu function mutat current orkambi
minor respond indic prescrib orkambi meaning
heterozyg patient popul
pulmonologist prescrib orkambi one mutat one
residu function mutat indic either orkambi
approv group patient ivacaftor kalydeco util instead
pulmonologist prescrib orkambi cf patient one
mutat one residu function mutat reason given
patient/famili request potenti improv lung function/good respons
therapi potenti diseas modifi effect therapi
pulmonologist year practic note
hope portion diseas would respond treatment report
on-going trial show seem effect patient
sentiment echo number respons speak high unmet need
patient popul
question pleas review follow efficaci safeti profil doublet regimen
tezacaftor/ivacaftor recent publish major peer-review medic journal
assum doublet
tezacaftor/ivacaftor regimen approv treat homozyg mutat cf
patient
mani insert sub-seg cf popul patient
medic month approv
 mani insert sub-seg cf popul patient
medic month approv
present risk/benefit profil tez/iva recent nejm
public homozyg patient pulmonologist report broad
penetr among rang orkambi-elig homozyg patient
interestingli consist pulmonologist survey group
pulmonologist ascrib minim penetr tez/iva
survey respond also one report
high level satisfact orkambi
convers survey respond indic high rate tez/iva uptak
necessarili correl high orkambi dissatisfact
survey data support vrtx assert variou earn call investor
meet base pulmonologist appreci risk/benefit profil
orkambi continu prescrib drug upon tez/iva approv
question assum doublet tezacaftor/ivacaftor cf regimen approv treat
cf one mutat one residu function mutat patient
 mani insert sub-seg cf popul patient
medic month approv
mani insert sub-seg cf popul patient
medic month approv
patient popul one mutat one residu function mutat
survey respond seem less enthusiast homozyg patient
question expect monotherapi ivacaftor kalydeco
demonstr efficaci penetr patient popul
interestingli subgroup survey respond
indic aggress potenti uptak tez/iva patient popul
month month
survey respond indic zero uptak tez/iva
month indic definit unmet need patient popul even
kalydeco approv popul
exhibit potenti market share tez/iva one one residu function mutat
question pleas take moment review follow efficaci data orkambi
label efficaci tabl
chang measur efficaci would need see order
switch patient current take orkambi new tezacaftor/ivacaftor doublet regimen
number pulmonari exacerb absolut chang
question sought ascertain pulmonologist expect level switch
homozyg patient orkambi tez/iva base strictli efficaci
appar outright switch orkambi tez/iva might realist mani
pulmonologist expect high rel tez/iva phase data
pleas observ pulmonologist expect two measur
cfq-r line/below phase phase data report
variou triplet combin similar patient
exhibit efficaci threshold expect switch orkambi
question pleas take moment review follow safeti data orkambi
label safeti tabl see
look side effect profil orkambi label reduct
follow side effect would need see order switch patient current take
orkambi new tezacaftor/ivacaftor doublet regimen approv
expect level switch base strictli safeti profil high tez/iva
lower rate respiratori advers event sell point patient
good candid orkambi discontinu drug
exhibit safeti threshold expect switch orkambi
question triplet regimen approv year percent
elig homozyg cf patient estim would
homozyg patient orkambi
 homozyg patient tez/iva
 homozyg patient ivacaftor
attempt gaug outstand satisfact dissatisfact current
approv therapi orkambi kalydeo ivacaftor variou patient subtyp
tez/iva clearli winner henc note orkambi
kalydeco still hold place drug armamentarium pulmonologist
util epocr hcpview third parti outsourc servic recruit conduct
physician survey survey launch decemb conclud
decemb survey particip compens epocr hcpview
particip
screen physician base follow particip criteria
primari specialti
approxim mani cystic fibrosi cf patient current treat
allow
less termin
experi prescrib orkambi
termin
familiar vertex pipelin investig therapi cf
includ tezacaftor/ivacaftor combin expect approv earli
triplet regimen develop
confirm subject confidenti non-disclosur
oblig rel subject issuer inform provid
constitut materi non-publ inform regard issuer
secur otherwis disclos share violat applic secur
law rule regul fiduciari duti
base criteria total physician complet survey full survey
question list
current cystic fibrosi cf patient percent follow
 one mutat one residu function mutat
 one mutat one minim function mutat
percent current cystic fibrosi cf patient follow
genotyp prescrib orkambi
 one mutat one residu function mutat
 one mutat one minim function mutat
current cystic fibrosi cf patient elig treatment orkambi
 start orkambi sinc discontinu due respiratori side
cf patient current prescrib orkambi percentag would
character treatment outcom breakdown
highli effect well toler
 effect well toler
 effect somewhat well toler
moder effect well toler
 moder effect somewhat well toler
 effect poorli toler
 moder effect poorli toler
 poor efficaci toler
percent cf patient one mutat one residu
function mutat current orkambi pleas comment
prescrib orkambi patient
pleas review follow efficaci safeti profil doublet regimen
tezacaftor/ivacaftor recent publish major peer-review medic journal
figur tezacaftor/ivacaftor efficaci data cf patient homozyg mutat
figur tezacaftor/ivacaftor safeti data cf patient homozyg mutat
figur tezacaftor/ivacaftor efficaci data cf patient one mutat one residu function
figur tezacaftor/ivacaftor safeti data cf patient one mutat one residu function
assum doublet tezacaftor/ivacaftor regimen approv treat homozyg
mutat cf patient
treatment naiv homozyg cf patient medic
month approv medic month approv
 current orkambi-tr homozyg cf patient
medic month approv medic month
 current orkambi-discontinu homozyg cf
patient medic month approv medic month
approv
assum doublet tezacaftor/ivacaftor cf regimen approv treat cf
patient one mutat one residu function mutat
treatment-nav cf patient one mutat one
residu function mutat medic month approv
medic month approv
 current orkambi-tr cf patient one mutat
one residu function mutat medic month approv
medic month approv
 current orkambi-discontinu cf patient one
mutat one residu function mutat medic month
approv medic month approv
pleas take moment review follow efficaci data orkambi label
chang measur efficaci would need see order
switch patient current take orkambi new tezacaftor/ivacaftor doublet regimen
number pulmonari exacerb absolut chang
pleas take moment review follow safeti data orkambi label
reduct follow side effect would need see order
switch patient current take orkambi new tezacaftor/ivacaftor doublet regimen
triplet regimen approv year percent elig
homozyg cf patient estim would
orkambi
 tezacaftor/ivacaftor
 ivacaftor monotherapi
respondentspecialtyyear practicingpractic practic offic practic offic practic offic practic offic offic practic offic offic offic physician practic offic practic offic practic offic practic offic physician practic offic pediatr physician practic offic physician physician physician practic offic base vertex pharmaceut
statement revenu royalti collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair charges- total cost expens incom loss oper interest incom interest expens incom expens incom loss provis benefit incom tax provis benefit incom net incom loss net incom loss attribut vertex dilut share outstand sale oper outperform
